Workflow
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
BDRXBiodexa Pharmaceuticals PLC(BDRX) Newsfilter·2024-01-22 13:30

Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024 CARDIFF, United Kingdom, Jan. 22, 2024 (GLOBE NEWSWIRE) – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs including Type 1 diabetes and rare / orphan brain cancers, today announced that Stephen Stamp, CEO and CFO of Bi ...